Towards Reduction or Substitution of Cytotoxic DMSO in Biobanking of Functional Bioengineered Megakaryocytes

• Published in: International journal of molecular sciences Vol. 21; no. 20; p. 7654
• Main Authors: Pogozhykh, Denys, Eicke, Dorothee, Gryshkov, Oleksandr, Wolkers, Willem F, Schulze, Kai, Guzmán, Carlos A, Blasczyk, Rainer, Figueiredo, Constança
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 16.10.2020; MDPI
• Subjects: Animals; Apoptosis; Availability; biobanking; Biobanks; Bioengineering; Blood Platelets - cytology; Blood Platelets - drug effects; Blood Preservation - methods; Bone marrow; Cell culture; Cells, Cultured; Contamination; Cryopreservation; Cryoprotective Agents - toxicity; Cytotoxicity; Dimethyl Sulfoxide - toxicity; Donor materials; Good Manufacturing Practice; Humans; Immunology; In vivo methods and tests; induced pluripotent stem cells (iPSC); Induced Pluripotent Stem Cells - cytology; Induced Pluripotent Stem Cells - drug effects; Logistics; Megakaryocytes; Megakaryocytes - cytology; Megakaryocytes - drug effects; Mice; Mice, SCID; mouse model; platelets; Population; Shelf life; Thrombocytopenia; Transfusion; propane-1,2-diol; dimethyl sulfoxide; megakaryocytes; biobanking; mouse model; ethylene glycol; induced pluripotent stem cells (iPSC); transfusion; cytotoxicity; platelets

Donor platelet transfusion is currently the only efficient treatment of life-threatening thrombocytopenia, but it is highly challenged by immunological, quality, and contamination issues, as well as short shelf life of the donor material. Ex vivo produced megakaryocytes and platelets represent a pro...